News from the Institute

In their publication researchers from IBC2 and collaborating universities have discovered a way to prevent harmful TDP-43 aggregates in cells under stress by redirecting the protein to the cell’s own repair system—offering promising new strategies for treating ALS and other neurodegenerative diseases.

Martin Wegner, a former member of IBC2 has received the Alumni Doctorate Award at the Dies Academicus of the Medical Faculty at Goethe University for his PhD thesis.

Targeted protein degradation (TPD) is an emerging therapeutic strategy that hijacks the cellular recycling machinery to degrade and remove disease causing proteins. The E3 ligase Cereblon (CRBN) is the central player for this process. Small molecule drugs recruit disease relevant proteins to the CRBN surface, which are then marked for degradation and removed by the cells.

For the seventh consecutive year, IBC2 Director Ivan Đikić has been named as a Highly Cited Researcher recognizing his exceptional impact in the field. His research papers have ranked among the most cited from 2013 to 2023 in the two categories “Biology and Biochemistry” and “Molecular Biology and Genetics”, as recorded by Web of Science.